X4 Pharmaceuticals, Inc (XFOR)
X4 Pharmaceuticals develops and sells oral treatments for rare blood diseases, led by XOLREMDI (mavorixafor) for WHIM syndrome. It last closed at $3.35 on Nov 2. XFOR reports earnings on Wed, Nov 4, 2026.
Key Stats
Last 12 monthsNot reported for this period.
From XFOR's SEC filings, latest 10-Q for the period ending Jun 30, 2026 (filed Aug 6). Last 12 months adds up the four latest quarters.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Jul 10 | Wells Fargo | Initiated | Buy | $11 |
| Jun 2 | Leerink Partners | Initiated | Buy | $12 |
Technical Analysis
The stock is 11% above its 20 day and 1% above its 50 day average. It is 13% below its 200 day average, so the longer trend is down. Momentum is strong (RSI 60). The nearest support is the 50 day average at $3.31, and the nearest resistance the Pivot at $3.36.
| RSI (14) | 60.33 | Strong, overbought above 70 | Neutral |
| MACD | 0.05 | Above its signal line | Bullish |
| Stochastic | 87.1 | Near the top of its range | Overbought |
| ADX (14) | 27.8 | Trending up | |
| Williams %R | -13.2 | Oversold below −80, overbought above −20 | Overbought |
| CCI (20) | 111.6 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +21.8% | Change over 10 sessions | Bullish |
| ATR (14) | $0.23 | Typical daily range, 6.8% of price |
| RSI (14) | 45.89 | Middle of its range | Neutral |
| MACD | -0.25 | Below its signal line | Bearish |
| Stochastic | 37.0 | Middle of its range | Neutral |
| ADX (14) | 15.5 | No clear trend | |
| Williams %R | -61.5 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -46.2 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −17.1% | Change over 10 sessions | Bearish |
| ATR (14) | $0.51 | Typical daily range, 15.3% of price |
What happened before
See how XFOR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How XFOR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
Whale Options Flow
90DNo whale options trades in XFOR in the last 90 days.
XFOR Institutional Ownership
Hedge fund holdings →| # | Fund | Shares | Of company | Value | Change | |
|---|---|---|---|---|---|---|
| 1 | Morgan Stanley | 9.5M | 9.54% | $44.2M | −5,713 | No change |
| 2 | Fmr LLC | 8.3M | 8.39% | $38.9M | +218K | Added |
| 3 | Bain Capital Life Sciences Investors, LLC | 8M | 8.04% | $37.2M | 0 | No change |
| 4 | Perceptive Advisors LLC | 7.9M | 8.00% | $37.0M | +1.2M | Added |
| 5 | Kalehua Capital Management LLC | 7.4M | 7.51% | $34.8M | 0 | No change |
| 6 | Saturn V Capital Management LP | 7M | 7.03% | $32.6M | +517K | Added |
| 7 | Empery Asset Management, LP | 6.9M | 6.99% | $32.4M | −2M | Trimmed |
| 8 | Deep Track Capital, LP | 5.9M | 5.93% | $27.5M | −461K | Trimmed |
| 9 | BlackRock, Inc. | 5.6M | 5.60% | $25.9M | +4.3M | Added |
| 10 | Nantahala Capital Management, LLC | 4.9M | 4.94% | $22.9M | +2.4M | Added |
| 11 | Vanguard Capital Management LLC | 3.7M | 3.75% | $17.4M | +218K | Added |
| 12 | NEA Management Company, LLC | 3.2M | 3.26% | $15.1M | 0 | No change |
| 13 | Rosalind Advisors, Inc. | 3.2M | 3.24% | $15.0M | 0 | No change |
| 14 | Braidwell LP | 2.9M | 2.95% | $13.6M | −350K | Trimmed |
| 15 | Blackstone Inc. | 2.7M | 2.71% | $12.5M | 0 | No change |
| 16 | Trails Edge Capital Partners, LP | 2.6M | 2.59% | $12.0M | 0 | No change |
| 17 | Bvf Inc/il | 2.2M | 2.25% | $10.4M | 0 | No change |
| 18 | Geode Capital Management, LLC | 2.1M | 2.12% | $9.8M | +1.2M | Added |
| 19 | Venrock Adviser, LLC | 1.9M | 1.95% | $9.0M | +1.6M | Added |
| 20 | Samsara Biocapital, LLC | 1.4M | 1.41% | $6.5M | −437K | Trimmed |
| 21 | State Street Corp | 1.3M | 1.31% | $6.1M | +892K | Added |
| 22 | Woodline Partners LP | 1M | 1.01% | $4.7M | 0 | No change |
| 23 | Goldman Sachs Group Inc | 917K | 0.92% | $4.3M | +34K | Added |
| 24 | Northern Trust Corp | 653K | 0.66% | $3.0M | +475K | Added |
| 25 | Vanguard Fiduciary Trust Co | 572K | 0.58% | $2.7M | +91K | Added |
- BlackRock, Inc.+4.3M sh$20.3M
- Nantahala Capital Management, LLC+2.4M sh$11.4M
- Venrock Adviser, LLC+1.6M sh$7.5M
- Perceptive Advisors LLC+1.2M sh$5.6M
- Geode Capital Management, LLC+1.2M sh$5.4M
- State Street Corp+892K sh$4.2M
- Empery Asset Management, LP−2M sh−$9.4M
- Stempoint Capital LP−1.7M sh−$7.0M
- Millennium Management LLC−1.2M sh−$5.0M
- Susquehanna International Group, LLP−842K sh−$3.9M
- Deep Track Capital, LP−461K sh−$2.2M
- Samsara Biocapital, LLC−437K sh−$2.0M
- Indivisible PartnersSold out−10K shOct 26
- Creative PlanningTrimmed−2,564 shNov 2
- Farther Finance Advisors, LLCNew+789 shOct 8
- GAMMA Investing LLCNew+385 shOct 8
- ProShare Advisors LLCTrimmed−55 shOct 29
- Sterling Capital Management LLCAdded+23 shOct 22
- Caitong International Asset Management Co., LtdTrimmed−19 shOct 29
- SBI Securities Co., Ltd.Added+2 shOct 22
From SEC Form 13F filings by funds managing over $100 million, as of Jun 30, 2026. Changes compare each fund with its own Q1 2026 filing. "Held by funds" adds up the shares every 13F filer reported, over shares outstanding. Filings come up to 45 days after the quarter ends. Put/call compares the value of puts and calls funds reported ($0 in puts, $1.2M in calls), leaving out market makers and bank trading desks. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XFOR is in one of them and how their past XFOR trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered XFOR in an article yet. Here's the latest on the wider market.
About X4 Pharmaceuticals
X4 Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts, that develops and sells treatments for rare blood diseases. Its main product, XOLREMDI (mavorixafor), is an oral capsule approved in the United States for WHIM syndrome, a rare immune disorder, and patients can obtain it through a specialty pharmacy. The company is also developing mavorixafor for chronic neutropenia, a rare blood condition, and works with partners to commercialize its products outside the United States.
- Headquarters
- Boston, MA